A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

All tumor types are now closed for enrollment:

Triple Negative Breast Cancer

Gastric Cancer

Pancreatic Cancer

Small Cell Lung Cancer

Bladder Cancer

Ovarian Cancer

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Subjects with histologically confirmed locally advanced or metastatic disease of the
following tumor types:

- Triple Negative Breast Cancer

- Gastric Cancer

- Pancreatic Cancer

- Small Cell Lung Cancer

- Bladder Cancer

- Ovarian Cancer

- Subjects must have measurable disease

- Eastern Cooperative Oncology Group (ECOG) of 0 or 1

- Adequate hematological and organ function as confirmed by laboratory values

Exclusion Criteria:

- Active brain metastases or leptomeningeal metastases

- Subjects with active, known or suspected autoimmune disease

- Subjects with a condition requiring systemic treatment with either corticosteroids
(>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
days of treatment

- Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or
checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
anti-CTLA-4 antibody, including Ipilimumab; or other medicines specifically targeting
T cell is also prohibited